Search
1,558 results found
Vinge | Sweden, European Union | 11 Jun 2019
Swedish Patent and Market Court of Appeal seeks clarification of the scope of the SPC Regulation in relation to new uses - refers question to the CJEU
In the beginning of May 2019 the Swedish Patent and Market Court of Appeal, requested a preliminary ruling from the Court of Justice of the European
Winston & Strawn LLP | USA | 23 Apr 2019
eDiscovery Advantage, Volume 5, Issue 1
The Winston & Strawn LLP eDiscovery and Information Governance Group (the "eDiscovery Group") is pleased to be able to offer our insights into the
Katz Marshall & Banks LLP | USA | 17 Apr 2019
Pharmaceutical Whistleblower Awarded $1.8M for Unlawful Retaliation
New Jersey’s Conscientious Employee Protection Act, N.J. Stat. 34:19-1 et seq. (“CEPA”), has resulted in another substantial whistleblower victory
Preu Bohlig & Partner | European Union, Germany | 16 Apr 2019
Reimbursement of Off-Label Use - Barriers and Limitations
One of the fundamental principles of EU pharmaceutical law is that a medicinal product may only be placed on the market on the basis of a marketing
Bird & Bird | Belgium, European Union | 5 Feb 2019
"Effective enforcement of EU competition rules in the pharmaceutical law remains a matter of high priority"
So notes the Commission's report on competition enforcement in the pharmaceutical sector (2009-2017) published at the end of January 2019. Who
McGuireWoods LLP | USA | 23 Jan 2019
Courts Issue Conflicting Work Product Doctrine Opinions: Part I
Ironically, federal and state courts applying their succinct work product rules exhibit more diversity than when construing the more complex and
Fenwick & West LLP | USA | 18 Dec 2018
Patent Owners Win as Federal Circuit Reins in Gilead and AbbVie Double Patenting Rulings
In a pair of patent owner victories, the U.S. Court of Appeals for the Federal Circuit issued decisions limiting the applicability of obviousness-type
Marshall Gerstein & Borun LLP | USA | 12 Dec 2018
Obviousness-Type Double Patenting Does Not Invalidate a Patent Term Extension
The Federal Circuit recently addressed the interplay between the statutory patent term extension (PTE) and the non-statutory doctrine of
Knobbe Martens | USA | 10 Dec 2018
Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical
A patent filed before the June 8, 1995 effective date of the Uruguay Round Agreements Act (URAA) has a 17 year term that begins on its issuance date
Pepper Hamilton LLP | USA | 10 Dec 2018
Obviousness-Type Double Patenting Just Became Less of a Problem for Innovators
The Federal Circuit recently issued a pair of decisions concerning the Gilead doctrine, which allowed later-issuing patents to be obviousness-type
